

**Supplementary Materials for**

**CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the  
Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma**

Sarah M. Larson, et al.


Correspondence to: [yvchen@ucla.edu](mailto:yvchen@ucla.edu)

**This file includes:**

Figs. S1 to S5


Captions for Figs. S1 to S5

## Supplementary Figure S1



**Supplementary Fig. S1. CART19/20 cell product characteristics. (A)** T-cell subtype distribution in cryopreserved CART19/20 cell products, with data segregated for CD4<sup>+</sup> and CD8<sup>+</sup> populations. Results indicate CD4<sup>+</sup> T cells are more enriched in the central-memory phenotype compared to CD8<sup>+</sup> T cells. Te/exh: effector/exhausted T cells, CD45RA<sup>+</sup>/CD45RO<sup>-</sup>/CD62L<sup>-</sup>; Tem: effector-memory T cells, CD45RA<sup>-</sup>/CD45RO<sup>+</sup>/CD62L<sup>-</sup>; Tcm: central-memory T cells: CD45RA<sup>-</sup>/CD45RO<sup>+</sup>/CD62L<sup>+</sup>; naïve: CD45RA<sup>+</sup>/CD45RO<sup>-</sup>/CD62L<sup>+</sup>. **(B)** Viability of cell product during *ex vivo* manufacturing. Data are shown with color coding by patient (left), by whether starting cell population underwent CD14/CD25 depletion (middle), and by disease indication (right).


## Supplementary Figure S2




**Supplementary Fig. S2. CD14/CD20 depletion did not significantly alter regulatory T (Treg) cell content in CART19/20 cell product and in patient peripheral blood post infusion.** Intracellular staining of starting (unactivated) T<sub>N/MEM</sub> population, CART19/20 final product, and patient PBMC collected 14 days post CART19/20 infusion. FOXP3<sup>+</sup> frequency is shown as a percentage of CD3<sup>+</sup>CD4<sup>+</sup> T cells.

## Supplementary Figure S3


### A



### B




### C



**Supplementary Fig. S3. Patient 009 exhibited elevated cytokine, C-reactive protein (CRP), and ferritin levels prior to and after CART19/20 cell infusion. (A)** Serum levels of various

cytokines measured by Luminex multiplex assay. **(B)** CRP levels for Patient 009 (left) and all patients (right). **(C)** Ferritin levels for Patient 009 (left) and all patients (right).


# Supplementary Figure S4




**Supplementary Fig. S4. PET scans taken for all patients treated with CART19/20 cell therapy.**

## Supplementary Figure S5

**A**



**B**



**Supplementary Fig. S5. T cell populations become CD8-dominant post CART19/20 cell infusion.** % CD8<sup>+</sup> among (A) CAR-expressing T cells and (B) all CD3<sup>+</sup> T cells was quantified by flow cytometry. Data are shown for CAR-T cells only up to day 90 post infusion as values post day 90 become unreliable due to low CAR<sup>+</sup> cell count detected by flow. FP: final product (i.e., cryopreserved CART19/20 cells).